Neurocrine Biosciences NBIX Free cash flow margin
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Based on trailing twelve months.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's free cash flow margin?
- Neurocrine Biosciences (NBIX) reported free cash flow margin of 26.8% in Q1 2026.
- How has Neurocrine Biosciences's free cash flow margin changed year-over-year?
- Neurocrine Biosciences's free cash flow margin increased by 31.3% year-over-year, from 20.4% to 26.8%.
- What is the long-term trend for Neurocrine Biosciences's free cash flow margin?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's free cash flow margin has grown at a -3.9% compound annual growth rate (CAGR), from 105.4% to 89.7%.
- What does free cash flow margin mean?
- How much real, spendable cash each sales dollar generates after reinvestment.
- How do you interpret free cash flow margin?
- A high and rising FCF margin is the hallmark of a cash-generative business. Persistent gaps between net margin and FCF margin warrant a look at working capital or capital intensity.
- How does free cash flow margin compare across companies?
- Strong cross-company quality signal; capital-light compounders post structurally higher FCF margins than asset-heavy peers.